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4 
ESCAPE at a glance 
Objectives of the project 
ESCAPE — the European Syringe Collection and Analysis Project Enterprise — aims to identify the range of 
substances being used by people who inject drugs in a small number of cities in Europe and to monitor 
changes in patterns of use over time. It is intended that this will provide timely, city-level data that can 
complement other information and indicators on drug consumption and potential emerging health threats in 
the region. 
A growing network 
A group of European researchers developed an innovative method to obtain information on injected 
substances by chemically analysing the residual content of used syringes and initiated a first round of data 
collection, conducted in six cities, in 2017. This report presents results from the second and third rounds of 
data collection, which took place in 2018 and 2019, respectively. Syringes were collected from the bins of 
street automatic injection-kit dispensers and at harm reduction services in eight European cities: Amsterdam 
(2019), Budapest (2018-19), Cologne (2018-19), Helsinki (2018-19), Lausanne (2018-19), Oslo (2019), Paris 
(2018-19) and Vilnius (2019). The contents of 988 (2018) and 1 330 (2019) used syringes were analysed in 
seven laboratories using chromatographic and spectroscopic methods. 
Main results 
Injected substances vary between and within cities. With the exception of Vilnius (2019), traces of stimulants 
(cocaine, amphetamines and synthetic cathinones) were found in a high proportion of the syringes tested in 
each of the cities. The proportion of syringes containing heroin was high and stable over time in half of the 
participating cities. Injection of opioid substitution medications, namely buprenorphine and methadone, as well 
as benzodiazepines, is common in Helsinki, Vilnius and Lausanne. In 2019, carfentanil, a very potent opioid, 
was detected in a third of syringes from Vilnius. Overall, a third of the syringes tested contained residues of 
two or more substances from different drug categories in 2018 and 2019, which confirms that people who 
inject drugs often inject more than one psychoactive substance. The most frequent combination was a mix of 
a stimulant and an opioid; benzodiazepines were often found in syringes that also contained traces of opioids. 
Main limitations 
The high proportion of syringes containing residues of stimulants could reflect a higher frequency of injecting 
among stimulant users than among non-stimulant users, rather than a higher prevalence of stimulant use than 
other drug use among people who inject drugs. Drugs found in syringes may originate from blood drawn into 
the syringe during an injection, that is, from drugs consumed prior to the injection, possibly through other 
modes of administration. It was not possible to distinguish a syringe containing residues of multiple drugs that 
had been used once from a syringe that had been reused by one or several users. 
Key messages 
The study provides local and timely information that can be used for city-level monitoring and interventions. 
The injection of stimulants has implications for the risk of blood-borne and sexually transmitted infections such 





as HIV and hepatitis B and C viruses. The injection of potent opioids such as carfentanil, as well as the 
injection of multiple substances, elevates the risks of adverse health consequences and overdose deaths. 
What’s next? 
The 2020 syringe collection campaign will include more sites and reach a total of 10 sentinel cities throughout 
Europe. It will also assess the impact, if any, that the coronavirus disease (COVID-19) pandemic has had on 
injecting drug use in these cities. 
Study rationale 
While evidence from drug treatment centres suggests that injecting drug use is declining among heroin clients 
in the European Union (EMCDDA, 2020b), the burden of disease associated with injecting remains high 
(Degenhardt et al., 2017). The risk of overdose death and infectious diseases associated with this mode of 
administration is also high. The injection of stimulants — including amphetamines, cocaine and synthetic 
cathinones — has been linked to increased risk of HIV and hepatitis C virus (HCV) transmission, through 
increased frequency of use and sharing of injecting paraphernalia (Arendt et al., 2019). Knowledge of what 
substances are being injected in a city or country is important to guide prevention strategies and plan the 
provision of treatment, as well as to inform law enforcement agencies. Furthermore, identifying associated risk 
factors, such as the use of multiple substances and/or the reuse of injecting material, is useful to assess and 
improve harm reduction interventions. 
Available data on the substances injected by users are largely based on self-reports collected in drug 
treatment registries or ad hoc surveys. Data from drug treatment centres collated at the national level show 
that the majority of people entering treatment who report injection as their main mode of administration identify 
an opioid (usually heroin) as their primary problem drug. While these data are useful, they are generally 
available only after some delay. Moreover, people who inject drugs may not wish to disclose which 
substances they inject or may not be aware of the actual composition of the substances they inject. Little is 
known about people who inject drugs who are not reached by drug services. To address such gaps in the 
data, a group of European researchers developed an innovative method to obtain information on injected 
substances by analysing the residual content of discarded syringes collected from the bins of street automatic 
injection-kit dispensers or at harm reduction services (Néfau et al., 2015; Lefrançois et al., 2016). 
The European Syringe Collection and Analysis Project Enterprise (ESCAPE) was established in 2017 by the 
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), starting with a network of six sentinel 
European cities: Amsterdam, Budapest, Glasgow, Helsinki, Lausanne and Paris. It aimed to identify which 
drugs were injected in the participating cities by analysing the content of used syringes. A report on the first 
campaign was published by the EMCDDA (EMCDDA, 2019a). Since the first campaign, the network has been 
extended to include three additional cities: Cologne, Oslo and Vilnius. This report provides an overview of the 
main findings of the 2018 and 2019 campaigns, presenting persisting patterns and new trends at the city level. 






Syringe collection, preparation and analysis 
In each of the participating cities, a local research team was responsible for the sampling, collection and 
preparation of the syringes. The contents of the syringes were analysed locally, except in Amsterdam where 
syringes were sent to the Lausanne research team for analysis. Depending on the availability of potential 
sampling locations and the local context, between one and six collection sites were selected in each city to 
maximise geographical coverage. 
The social and demographic characteristics of the people who inject drugs served by each site broadly 
reflected the heterogeneity found between and within European cities. The collection sites are described in 
Table 1. They included low-threshold facilities offering face-to-face needle and syringe programmes (NSPs), 
drug consumption rooms and street bins of automatic injection-kit dispensers. 
Syringes were collected between March and April 2018 (second campaign) and May and August 2019 (third 
campaign). The research teams aimed to collect 150 syringes per city per campaign, equally distributed 
across sites, which were considered feasible yet sufficiently representative samples. The number of syringes 
collected per site depended on the number of sites selected in each city; the minimum required sample size 
per site per year was set at 30 syringes. Where possible, syringes were collected from different containers to 
minimise the risk of collecting too many syringes from the same person who injects drugs. When collecting 
used syringes from automatic injection-kit dispenser bins, the syringes in the bins were shuffled before 
sampling. Syringes with damaged barrels were excluded. Standard 1-ml syringes were collected at all sites. 
Large volume syringes (> 1 ml) were collected in Amsterdam, Helsinki, Oslo and Vilnius. In Oslo, the research 
team mainly collected and tested detachable needles (Gjerde et al., 2020). In Helsinki and Paris, needleless 
syringes were excluded, while, in Amsterdam, syringes with a crooked needle were excluded. In Helsinki, 
Lausanne and Paris, syringes were visually assessed to identify broken needles and erased graduation 
marks, which were considered proxies for attrition and possible indications of reuse. 
To reduce the risks associated with handling used injection material, a number of safety precautions were 
taken, such as wearing personal protective equipment (including safety goggles, gowns and anti-scratch 
gloves), having access to a bleach basin and using sharps containers to recover syringes. 
Syringes were transported from the collection sites to the laboratory within 48 hours of being deposited, to 
limit degradation of the content. Once in the laboratory, syringes were stored at 4 °C (for analysis within 48 
hours) or at –20 °C (for analysis beyond 48 hours). Syringe contents were extracted with 1 ml of methanol: the 
syringe was filled and emptied five times and the contents were collected in a clean test tube (Figure 1). The 
recovered methanol solution was then filtered before analysis to eliminate solid particles, which could damage 
the analytical instruments. 
























TABLE 1  
Sociodemographic characteristics of populations living in the study sites and details of syringes analysed, 2017-19, ESCAPE network 








Syringe collection sites Number of syringes 
analysed 
Type of syringes 
collected or 
restrictions (e.g. 
> 1-ml syringes 
excluded) 
2017 2018 2019 
Amsterdam 860 000 
(density of 
5 042/km²) 
150-200 Not available 2017: three NSPs and two drug consumption rooms. One of the 
drug consumption rooms is located in the red-light district and 
also provides sterile syringes. It is the only drop-in centre with a 
shelter for women. The drug consumption room is located near 
the city centre and also aims to serve clients that are homeless 
and often economic refugees from other countries in the EU. 
Clients of these services are aged between 22 and 71 years and 
are socially vulnerable. Self-reported substance use includes 
use of heroin, cocaine, methadone, amphetamines, cannabis 
and alcohol. 
2019: the same three NSPs and two drug consumption rooms 
were used. In addition, five chemsex services near or in the city 
centre with needle dispensers on-site were sampled. Two of 
these are located in the red-light district and the other three are 
located within 500 metres of the city centre. Clients are men who 
have sex with men, aged 25-55. 
112 n/a 150 Only 1-ml syringes 
Budapest 2 000 000 
(density of 
3 314/km²) 






2017-18: one face-to-face NSP. This low-threshold service is 
located in a neighbourhood with low socioeconomic conditions, 
where there is a concentration of homeless people and sex 
workers. The area is also popular among tourists. 
2019: two sites were added in 2019, both located in the west of 
the city. One service provides drug counselling and a face-to-
face NSP. The other provides anonymous HIV and HCV 
screening and counselling, as well as a face-to-face NSP.  
300 150 185 1-ml syringes 













Syringe collection sites Number of syringes 
analysed 
Type of syringes 
collected or 
restrictions (e.g. 
> 1-ml syringes 
excluded) 
Cologne 1 081 701 
(density of 
2 700/km²) 
6 600  2018: five NSPs. Two are in the city centre where there is an 
open drug scene; clients are mostly homeless people. Another 
one is located in a mixed business/residential area and clients 
are people who inject drugs with more stable socioeconomic 
situations. The other two NSPs are located in two different 
residential areas characterised by high rates of unemployment. 
 
2019: one of the five NSPs had been replaced by the 2019 
campaign by a drug consumption room located in the city centre 
where there is an open drug scene and where clients are mostly 
homeless people.  
n/a 167 146 No restrictions 




8 500 2017: three of 
the five NSPs 
provided a total 
of 1 732 462 
needles and 
syringes 
2017: five NSPs. One site is in the eastern part of city centre, 
an area with social and health services for people who inject 
drugs, known for drug trade and drug users. A second site is in 
the northern part of the city centre, in a housing unit with 100 
residents who suffer from substance abuse and/or mental 
health problems. A third site is located close to the city centre, 
near a similar housing unit. The two remaining sites are 
located further east, one in a business and residential area 
with an open drug scene and open drug trade, and the other in 
a residential area with a higher than average concentration of 
government tenant housing complexes. 
 
2018-19: same sites as in 2017, with one additional NSP site 
located in north-eastern Helsinki. 
307 425 201 No restrictions 
Lausanne 144 597 
(density of 
3 395/km²) 
Not available 2015: 100 000 
syringes were 
distributed 
2017-19: there is only one automatic injection-kit dispenser bin 
in Lausanne. It is located in the central neighbourhood served 
by two metro stations. During daytime, people from diverse 
socioeconomic backgrounds use this area. In the evening, it 
has significant nightlife activity and hosts marginalised groups. 
297 150 150 Only 1mL syringes 
Oslo 681 000  
(density of 1 
1 550 2019: ~1.4 
million needles 
2019: three services, namely one NSP, one supervised 
injection room and one low-threshold service for people who 
n/a n/a 163 55 syringes and 108 
needles (without 













Syringe collection sites Number of syringes 
analysed 
Type of syringes 
collected or 
restrictions (e.g. 
> 1-ml syringes 
excluded) 
532/ km²) were dis ributed inject drugs that is open 24 hours a day, offering medical 




Paris 2 220 445 
(density 
21 067/km²) 





2015: 656 000 
syringes were 
distributed 
2017-19: five automatic injection-kit dispenser bins. Three sites 
are located next to train stations. In one of these sites, users of 
automatic injection-kit dispensers include low-income and 
homeless people who inject drugs. The other two stations are 
busy public transport hubs frequented by people from diverse 
socioeconomic backgrounds. The remaining two sites are 
located near metro stations in neighbourhoods with well-
integrated populations. One of the latter is famous for its 
nightlife.  
360 96 185 Only 1-ml syringes 







4 572)  
2019: 240 000 
syringes were 
distributed 
2019: three collection sites across Vilnius at low-threshold 
facilities where NSPs are implemented. These are the only 
facilities in Vilnius where syringes are collected. 
n/a n/a 150 No restrictions 
 






Syringes were tested for more than 120 drugs, depending on the analytical method used (see Appendix 1). In 
addition, syringes were screened for the presence of some metabolites, degradation products and adulterants 
(see the box ‘Definitions used in the study’). Any syringe testing positive for 6-MAM (6-monoacetylmorphine, a 
metabolite of heroin) in the presence of morphine or codeine or meconin (degradation products of heroin) was 
assumed to have once contained heroin and was reclassified as a ‘heroin syringe’. Inactive diluents and 
binders were not considered in this study. The list of substances tested for is provided in Appendix 1, which 
also details which cities performed each test. 
The analytical methods employed in this project have been used previously in similar studies: gas 
chromatography (GC), ultra-high- or high-performance liquid chromatography (UHPLC or HPLC) coupled with 
mono or tandem mass spectrometry (MS or MS/MS) (Néfau et al., 2015; Lefrançois et al., 2016) (Table 2). In 
Cologne, Oslo and Paris, chemists used a target-compounds method, allowing them to detect only the 
compounds listed in Appendix 1. In Helsinki, the laboratory analysed each syringe with both targeted and non-
targeted screening methods for the sensitive detection of over 1 200 compounds. Samples from Amsterdam, 
Budapest, Lausanne and Vilnius were analysed using a screening method that could potentially detect any 
compound, including all those listed in Appendix 1. 
TABLE 2  
Participating laboratories and laboratory methods, 2018 and 19, ESCAPE network 




Unit of Forensic Toxicology and Chemistry, 
University Centre of Legal Medicine, Lausanne-
Geneva 
Screening method GC-MS 
Budapest 
Toxicology Laboratory of the Institute of 
Forensic Medicine of the University of Debrecen 
Screening method GC-MS 
Cologne 
Institute of Forensic Medicine, Medical Centre, 
University of Freiburg 




Forensic Toxicology Unit of the National 
Institute for Health and Welfare 
Targeted and non-targeted 
screening methods (~1 200 drugs 
in database and possibility to 




University Institutes at the University Centre of 
Legal Medicine, Lausanne-Geneva 
Screening method GC-MS 
Oslo 
Department of Forensic Sciences, Oslo 
University Hospital 
Targeted screening method UHPLC-MS/MS 
Paris 
Laboratory of Public health and Environment, 
Paris-Sud University 
Targeted screening method HPLC-MS/MS 
Vilnius 
Lithuanian Police Forensic Science Centre and 
Forensic Science Centre of Lithuania 
Screening method GC-MS 
Note: QTOF/MS, quadrupole time-of-flight mass spectrometry; MSn sequential mass spectrometry 





All drugs were grouped according to their public health relevance and on the basis of their shared 
characteristics into 18 drug categories: cocaine, heroin, morphine, buprenorphine, naloxone, methadone, 
ketamine, amphetamines, fentanyl and derivatives, other opioids, synthetic cathinones, synthetic 
cannabinoids, benzodiazepines, piperidines, MDMA, other medications, other amphetamines and other drugs 
(see Appendix 1). Some drug categories (e.g. cocaine) include a single drug, while others (e.g. synthetic 
cathinones) include several drugs. The results of the 2018 and 2019 campaigns are presented by drug 
category. Only syringes that were positive for at least one psychoactive substance (excluding metabolites and 
adulterants) were included in the denominator for the computation of the proportions (main results shown in 
Figures 2 and 3). In the analysis, any syringe testing positive for 6-MAM in the presence of morphine or 
codeine or meconin was assumed to have once contained heroin and was reclassified as a ‘heroin syringe’ 
(see Definitions used in the study’). 
Definitions used in the study 
Adulterant: a pharmacologically active compound that dealers mix with drugs to increase the volume of the product 
to maximise profits. For instance, levamisole — originally an anthelmintic medication, which has some 
antidepressant properties — is a common adulterant of cocaine. Pharmacologically inert diluents (such as sugar) 
were not screened for in this study. 
By-product of production: drugs that are the result of the production process of another drug. For instance, 
codeine traces might be found in heroin. 
Degradation product: a compound resulting from the natural breakdown of a drug over time. The degradation of a 
drug can occur in the syringe. For instance, heroin will naturally degrade into 6-MAM and morphine. In the analysis, 
any syringe testing positive for 6-MAM in the presence of morphine or codeine or meconin was assumed to have 
once contained heroin and was reclassified as a ‘heroin syringe’. 
Drug: a psychoactive substance consumed with the aim of altering the user ’s mood and perception, through its 
effect on the central nervous system. 
Drug category: to simplify the presentation of results for the large number of substances covered in this study, 
drugs were grouped into 17 drug categories according to their public health relevance and on the basis of their 
shared characteristics. The categories may thus be based on a combination of chemical, pharmacological and use 
characteristics. For example, heroin and methadone are reported separately from ‘other opioids’ and ‘other 
medications’, respectively. Some drug categories (e.g. cocaine) include a single drug, while others (e.g. synthetic 
cathinones) include several drugs. 
Metabolite: a residue of a drug after it is broken down in the body. Metabolites can be found in the blood, urine or 
faeces of users after consumption of the drug regardless of the route of administration. Blood containing metabolites 
can enter a syringe during injection. In this study, tests were carried out for metabolites of heroin (6-MAM), cocaine 
(benzoylecgonine) and benzodiazepines (7-aminoclonazepam). Some metabolites, for instance 6-MAM, can also 
result from degradation. Syringes testing positive for only metabolites were excluded from the analysis. 
 
  







The 2018 campaign 
In 2018, the research teams analysed a total of 988 syringes from five cities (Budapest, Cologne, Helsinki, 
Lausanne and Paris). At least one drug was found in 899 syringes (91 %), while 90 syringes (9 %) did not test 
positive for any drug; of these, 70 did not test positive for any substance screened for and 30 tested positive 
for only metabolites or adulterants. There are four possible explanations for none of the tested substances 
being detected in a syringe: the syringe had not been used; it had been used and then thoroughly washed; it 
had been used but any substance(s) had degraded to undetectable levels; or it had been used to inject 
substances such as pharmacologically inactive compounds or drugs not included in the screening protocol. 
Traces of 48 different drugs were identified in the syringes analysed in the 2018 study. Overall, the drug 
categories most often found in the syringes were cocaine, heroin, cathinones, buprenorphine and 
amphetamines, with differences across cities (Figure 2). Cocaine was the most commonly detected drug in 
Cologne and Lausanne and was found in almost half of the syringes from Paris. Synthetic cathinones were 
found in half of the syringes from Paris and 43 % of the syringes from Budapest. In Helsinki, more than half of 
the samples tested positive for buprenorphine and 42 % for amphetamines. Heroin was found in half of the 
syringes from Cologne, 41 % of the syringes from Lausanne, 33 % of the syringes from Budapest and 20 % of 
the syringes from Paris. Benzodiazepines were found in a third of the syringes from Lausanne (Figure 2). Out 
of 899 syringes, 282 (31 %) contained multiple drugs (more than one) belonging to different drug categories. 
The 2019 campaign 
In 2019, the research teams analysed a total of 1 330 syringes from eight cities (Amsterdam, Budapest, 
Cologne, Helsinki, Lausanne, Oslo, Paris and Vilnius). At least one drug was found in 1 131 syringes (85 %), 
while 199 syringes (14 %) did not test positive for any drug; of these, 165 did not test positive for any 
substance screened for and 34 tested positive for only metabolites or adulterants. 
Traces of 41 different drugs were identified in the syringes analysed in the 2019 study. Overall, stimulants 
were found in the majority of syringes from Amsterdam (amphetamines), Budapest (synthetic cathinones), 
Cologne (cocaine), Paris (synthetic cathinones) and Lausanne (cocaine) (Figure 3). Opioids were found in the 
majority of syringes from Cologne (heroin), Helsinki (buprenorphine), Oslo (heroin) and Vilnius (methadone 
and carfentanil) (Figure 3). Out of 1 131 syringes, 358 (32 %) contained multiple drugs (more than one) 
belonging to different drug categories. 
  






Percentage of syringes by detected drug category, by city, ESCAPE, 2018 
 
FIGURE 3 
Percentage of syringes by detected drug category, by city, ESCAPE, 2019 
 





Some patterns confirmed 
Although the number of syringes collected does not directly reflect the number of drug users injecting drugs 
and the collection sites might not be representative of all people who inject drugs in the participating cities, 
some of the overall patterns and regional specificities identified in the first ESCAPE campaign, in 2017 
(European Monitoring Centre for Drugs and Drug Addiction, 2019), were confirmed by the 2018 and 2019 
campaigns. 
Regional specificities persist 
Despite global and European markets for drugs, strong regional specificities in terms of injected drugs 
persisted throughout the ESCAPE campaigns. This can be seen in cities that participated in at least two 
campaigns. High proportions of both buprenorphine and amphetamine syringes were a stable feature across 
all collection campaigns in Helsinki. The proportions of syringes testing positive for cocaine in Lausanne 
(72 % in 2017, 66 % in 2018, 79 % in 2019) and Cologne (69 % in 2018, 72.6 % in 2019) were remarkably 
high and stable over time. Similarly, the presence of benzodiazepines in syringes from Lausanne (23 % in 
2017, 29 % in 2018, 33 % in 2019) has been a recurrent local characteristic of the Swiss site. Many different 
drugs were detected in syringes from Paris (where all syringes were collected from automatic injection-kit 
dispenser bins), and the proportions of syringes testing positive for synthetic cathinones, cocaine, morphine 
and heroin were similar across campaigns. In Budapest, synthetic cathinones were the most commonly 
detected drug type in all three campaigns. 
Stimulant injecting is found in most sites 
The high proportion of syringes testing positive for stimulants was confirmed in 2018 and 2019 in all 
participating cities except for Vilnius. Commonly found stimulants in syringes included cocaine (Lausanne, 
Paris), synthetic cathinones (Budapest, Paris) and amphetamines (Helsinki). A high proportion of syringes 
containing stimulants was also observed in the two newly participating cities, joining in 2018 or 2019, with high 
proportions of syringes testing positive for cocaine in Cologne and for amphetamines in Oslo. These results 
suggest that injecting stimulants is a widespread practice among people who inject drugs in these European 
cities. Globally, injection of stimulants has recently been reported as a growing phenomenon and presents a 
major public health challenge (Farrell et al., 2019). The high prevalence of stimulants in syringes could be 
associated with a higher injecting frequency typical of stimulant use and with an increased level of HIV 
transmission (Giese et al., 2015; Arendt et al., 2019; McAuley et al., 2019). 
In some cases, the presence of stimulants could also be the result of traces of blood containing stimulants 
being drawn into the syringe during injection but having been consumed prior to injection, possibly through 
other modes of administration. However, data from low-threshold services (NSPs, drug consumption rooms) 
and surveys also point to high levels of stimulant injection among people who inject drugs (EMCDDA, 2018a; 
Kapitány-Fövény and Rácz, 2018). The exception to this pattern is in Vilnius where amphetamines were the 
most commonly found stimulant in 2019, detected in only four out of 132 syringes (3 %) (see section below 
‘Vilnius: carfentanil mixed with methadone’). 
Opioid substitution medications and benzodiazepines are injected in some cities 
Evidence shows that opioid substitution treatment reduces illicit opioid use, risk behaviour and mortality 
(EMCDDA, 2017). The main opioid substitution medications prescribed in Europe are methadone (63 % of 





substitution treatment clients) and buprenorphine (35 %); slow-release oral morphine and diacetylmorphine 
(medical grade heroin) are used to a much lesser extent (3 %) (EMCDDA, 2019b). The diversion and misuse 
of opioid substitution medications have been reported (EMCDDA and Europol, 2019) and the presence of 
these substances in syringes may be an indication of such misuse. 
As in 2017, buprenorphine was commonly found in syringes in the 2018 and 2019 campaigns in Helsinki 
(57 % in 2017, 67 % in 2018, 67 % in 2019) and to a lesser extent in Paris (8 % in 2017, 3 % in 2018, 7 % 
in 2019). In 2019, buprenorphine was also detected in seven syringes (4 %) from Oslo. While the rate of 
buprenorphine detection remains high in Helsinki, buprenorphine mixed with naloxone was lower in 2019 
than in previous campaigns. The proportion of syringes containing naloxone dropped from 11 % in 2017 to 
8 % in 2018 and 5 % in 2019. The main opioid substitution medication used in Finland is Suboxone®, which 
contains buprenorphine and naloxone (Kankaanpää et al., 2016). The 2019 results confirm that most of the 
buprenorphine that is injected in Helsinki is not diverted from locally prescribed medication , but seems to be 
smuggled from France via Sweden, as suggested by the evidence from drug seizures (EMCDDA and 
Europol, 2016). 
Overall, few syringes containing methadone were found in 2017 and 2018, and the same picture emerged 
from the 2019 campaign, except in Vilnius. The injection of methadone syrup is difficult but has been 
documented; it requires dilution in water and also often requires the use of large-volume syringes (sometimes 
larger than 20 ml), which were not sampled in most of the study cities. The fact that buprenorphine is more 
commonly prescribed in France and that more than half of methadone clients in France receive the 
medication in the form of capsules designed to prevent injection (Roux et al., 2011) could explain why 
methadone was detected in only 2.5 % (4/161) of the syringes analysed in Paris. Methadone was detected for 
the first time in 2019 in seven syringes from Cologne (5 %). However, the most striking result for methadone 
comes from the 2019 campaign in Vilnius, where methadone was found in 92 % of syringes testing positive 
for any drug (see section below ‘Vilnius: carfentanil mixed with methadone’). 
Evidence suggests that co-consumption of benzodiazepines increases the risk of overdose among high-risk 
opioid users; furthermore, injecting crushed and dissolved medications that are intended for oral 
administration puts users at higher risk of vascular complications and infections (Reynaud et al., 2002). While 
in Helsinki the detection of benzodiazepines was lower in 2018 (4 %) and 2019 (5 %) than in 2017 (11 %), it 
was higher and increased year on year in Lausanne (23 % in 2017, 29 % in 2018, 33 % in 2019). In 
Lausanne, all syringes testing positive for benzodiazepines in 2018 and 2019 contained midazolam. In 
Helsinki, there was greater variety, with midazolam, alprazolam, diazepam and temazepam being detected. In 
the 2019 campaign, benzodiazepines (clonazepam and alprazolam) were also detected in 10 needles (6 %) 
from Oslo. 
Combination of substances: opioids with stimulants 
Polydrug use can refer to the consumption of more than one drug by an individual over a certain period of 
time. It is associated with increased psychopathology, more risk behaviours, lower treatment adherence and 
worse health outcomes (Connor et al., 2014). Polydrug use is common among high-risk drug users. It includes 
simultaneous use (or co-use) of different drugs, such as the simultaneous injection of heroin and cocaine, 
known as ‘speedballing’. This pattern of use is difficult to assess with standard monitoring tools. The presence 
of multiple drugs in a syringe can be an indication of co-use and may help to identify commonly used 
combinations. 





Overall, in 2018, 32 % (285/899) of syringes containing drugs had traces of drugs from two or more drug 
categories (not taking into account adulterants and metabolites): 26 % of the syringes contained traces of 
drugs from two categories, 5 % from three categories and 1 % from four or more categories. A very similar 
pattern was observed during the 2019 campaign: 32 % (358/1 131) of syringes testing positive contained 
traces of drugs from two or more drug groups, 26 % contained traces of drugs from two categories, 5 % from 
three categories and 1 % from four or more categories. In 2019, the proportions of syringes containing drugs 
from two or more drug categories were highest in Cologne (57 %) and lowest in Budapest (6 %). 
The most frequently detected drug category combinations by city and year are shown in Table 3. Note that 
only the most frequently detected combinations are presented here; for example, in Cologne in 2019, a total of 
65 syringes contained a mix of only cocaine and heroin; this does not include the four syringes analysed 
containing cocaine, heroin and methadone. For a more detailed description of combinations, see Appendix 3. 
TABLE 3  
Most frequently detected drug category combinations found in syringes, by city and year, ESCAPE 
network 










Amsterdam 2018 n/a     
 2019 Amphetamines, MDMA 17 117 15 % 
Budapest 2018 Amphetamines, other amphetamines 4 141 3 % 
 2019 Cathinones, other medicines 3 108 3 % 
Cologne 2018 Cocaine, heroin 60 163 37 % 
 2019 Cocaine, heroin 65 146 45 % 
Helsinki 2018 Amphetamines, buprenorphine 31 387 8 % 
 2019 Amphetamines, buprenorphine 6 194 3 % 
Lausanne 2018 Cocaine, heroin 14 128 11 % 
 2019 Benzodiazepines, morphine 22 116 19 % 
Oslo 2018 n/a    
 2019 Amphetamines, heroin 33 157 21 % 
Paris 2018 Cathinones, cocaine 10 80 13 % 
 2019 Amphetamines, cathinones 12 161 7 % 
Vilnius 2018 n/a    
 2019 Fentanyl and derivatives, methadone 36 132 27 % 





Combinations of opioids and stimulants were most common in Cologne (cocaine and heroin), Helsinki 
(amphetamines, buprenorphine), Lausanne (cocaine and heroin in 2018) and Oslo (amphetamines and 
heroin). Combinations of different stimulants were most common in Amsterdam (amphetamines and MDMA), 
Paris (cathinones with either cocaine or amphetamines) and to a lesser extent Budapest (amphetamines and 
other amphetamines (N-acetylamphetamine) in 2018). A mixture of opioids (fentanyl and methadone) was the 
most common combination found in Vilnius, while combinations involving benzodiazepines were common in 
Lausanne (benzodiazepines and morphine in 2019). 
Changing patterns 
In addition to the relatively stable patterns and regional specificities described above, the ESCAPE network 
has identified a number of potentially new patterns of use in the course of the campaigns. These findings must 
be interpreted with caution, as sites might not be representative, the sample size is small and in some cities 
collection sites have changed over time, meaning that any new patterns may reflect a different source 
population rather than an actual change in drug use. However, these changes are worth describing and 
interpreting. 
Decline in cathinones and re-emergence of heroin in Budapest 
In Budapest, synthetic cathinones were found in the majority (80 %) of syringes collected and analysed in 
2017 (N-ethylhexedrone, 76 %; 4-chloro-alpha-PVP, 45 %). That same year, heroin was detected in only 6 % 
of syringes. Synthetic cathinones first appeared on the local drug market after the heroin shortage in 2011 and 
have since presented a substantial challenge for harm reduction services. For instance, the shift towards 
cathinones was linked to an increased frequency of injecting, the reuse and sharing of syringes and a higher 
HCV prevalence among stimulant users. The main cathinones injected in 2015 were pentedrone and MDPV 
(methylenedioxypyrovalerone) (Tarján et al., 2015). In the subsequent campaigns, however, the detection of 
synthetic cathinones declined along with the parallel re-emergence of heroin. Drugs of the synthetic 
cathinones group were still the most frequently detected but detection decreased from 80 % in 2017 to 43 % 
in 2018 and 55 % in 2019. In parallel, the proportion of syringes testing positive for heroin increased from 6 % 
in 2017 to 33 % in 2018 and 31 % in 2019. While N-ethylhexedrone and 4-chloro-alpha-PVP were the most 
frequently detected cathinones in the Hungarian capital in 2017 and 2018, 4-chloromethcathinone and 
mephedrone (4-MMC) topped the list in 2019. The relative decline in synthetic cathinones and the re-
emergence of heroin during the three campaigns concur with the decrease in the proportion of syringes 
containing drugs from two or more drug categories (from 13 % in 2017 to 6 % in 2019). 
Synthetic stimulants detected at new Amsterdam study sites 
The results from the 2017 campaign in Amsterdam contrasted sharply with the 2019 results. In 2017, almost 
all syringes (95 %) collected from four low-threshold services contained heroin, with cocaine identified in 
43 %. Two years later, amphetamines (69 %) and MDMA (26%) were the most frequently detected drug 
categories from syringes collected in the city. Ketamine was also detected in 8 % of syringes. The 2019 
collection sites included five additional automatic injection-kit dispenser sites near services for men who have 
sex with men. Amphetamines and ketamine are drugs commonly associated with chemsex among men who 
have sex with men (Achterbergh et al., 2020). The results of the 2019 campaign therefore reflect a change in 
the source population, rather than a change in drug use patterns over time. In accordance with this, the four 
sites where the sampling of syringes had occurred in 2017 (three low-threshold services providing NSPs and 
one drug consumption room) showed a stable trend in heroin and cocaine detection between 2017 and 2019. 





Injection of morphine replacing heroin in Lausanne 
The only observed emerging trend in Switzerland was the decrease in heroin use (from 36 % in 2017 to 16 % 
in 2019), with heroin use seemingly having been replaced by morphine consumption (the proportion of 
syringes containing morphine without heroin metabolites or heroin by-products went up from 6 % in 2017 to 
22 % in 2019). Opioid substitution treatment prescription practices have changed in Switzerland, with a 
relative decline in methadone prescriptions in favour of morphine prescriptions between 2015 and 2017 (2015: 
85 % methadone, 6 % morphine; 2017: 68 % methadone, 19 % morphine) (Stadelmann et al., 2019). While 
the injection of morphine sulphate has already been reported in Paris (Cadet-Taïrou and Gandilhon, 2014; 
Lermenier-Jeannet et al., 2017), this pattern of use has not commonly been reported by low-threshold facility 
surveys conducted in Switzerland (Lociciro and Casalini, 2018). In the 2019 ESCAPE study, morphine was 
commonly found with midazolam (19 % of all syringes tested positive for this combination). 
New sites 
Vilnius: carfentanil mixed with methadone 
The first collection campaign in Vilnius was conducted between June and July 2019. A total of 150 syringes 
were collected from three collection sites at low-threshold facilities where NSPs are implemented in the 
Lithuanian capital. At least one substance (including adulterants and metabolites) was found in 145 syringes; 
and 132 syringes contained at least one drug (excluding adulterants and metabolites). Methadone was 
detected in 92 % of syringes containing at least one drug (121/132), carfentanil (classified in the ‘fentanyl and 
derivatives’ drug category) was found in 33 % (43/132), methamphetamine (classified in the ‘amphetamines’ 
drug category) in 3 % (4/132), MDMA in 2 % (3/132), morphine in 2 % (2/132) and cocaine in 2 % (2/132). 
Diphenhydramine — classified in this study as an adulterant — was detected in 139 syringes. The 
combination of carfentanil and methadone was found in 36 syringes and was commonly mixed with 
diphenhydramine. This pattern was common to all three sites. 
Fentanyl and derivatives, such as carfentanil, are highly potent synthetic opioids that are present on the 
European illicit drug market and have been linked to several fatal drug poisonings (EMCDDA, 2018b). The 
combination of carfentanil and methadone adulterated with diphenhydramine is known to the police in Vilnius. 
Forensic evidence suggests the carfentanil-methadone mixture is purchased by users from the same supplier. 
While heroin used to be the most commonly injected drug among people who inject drugs in Vilnius, it has 
been replaced in the last five years by synthetic opioids. Police seizures first indicated that heroin was being 
mixed with carfentanil in 2016. In 2017, police data showed that methadone was replacing heroin in the 
carfentanil mix. It is possible that syringes in which methadone was detected without fentanyl had contained a 
carfentanil-methadone mixture, but that the carfentanil was present at such low levels that it was not 
detectable by the laboratory methods used. While field workers in Vilnius have noted that some users inject 
medicines such as benzodiazepines while consuming alcohol (known among users as ‘fool’s cocktail’), no 
benzodiazepines were detected in syringes collected during the 2019 campaign. 
Note that the other sites detecting fentanyl or derivatives were Cologne (one syringe containing fentanyl in 
2018 (1 %) and one in 2019 (1 %)), Oslo (one needle containing fentanyl in 2019 (1 %)) and Paris (two 
syringes containing fentanyl in 2019 (1 %)). 





Oslo: heroin and amphetamines 
In Oslo, injecting material was collected for the first time in 2019 from three drug services: one NSP, one 
supervised injection room and one low-threshold service for people who inject drugs that is open 24 hours a 
day, offering medical services, help with social services, food and shelter. In Oslo, people who inject drugs 
usually bring only their needles back to the NSP site (‘needle puck’) rather than entire syringes. Therefore, the 
research team in the Norwegian capital collected and analysed 108 needles (without a syringe) and 55 
syringes. 
In total, heroin was detected in 72 % (n = 113) of injecting devices, amphetamines in 50 % (n = 78), 
benzodiazepines (clonazepam) in 6 % (n = 10) and buprenorphine in 4 % (n = 7). Needles or syringes 
containing a mixture of heroin and amphetamine were common (21 %, n = 33). Other drug combinations 
found in Oslo included mixtures of heroin, amphetamine and benzodiazepines (3 %, n = 5), and heroin and 
benzodiazepines (3 %, n = 5). Overall, these results confirmed the results from surveys conducted in Oslo 
(Gjersing, 2017) linking high-risk drug use to injecting mainly amphetamines and opioids, primarily heroin. 
These results also confirm the trend of amphetamine replacing methamphetamine in the country, reflecting 
changes in the illicit drug market. Police data have shown that, during 2010-2013, methamphetamine was 
more often seized than amphetamine. This was reversed in later years, with seizure activity in the first half of 
2019 showing that 2 % of the total number of seizures were of methamphetamine, whereas 14 % were of 
amphetamine (Kripos, 2019). 
One of the collection sites (the drug consumption room) showed a higher proportion of needles/syringes 
testing positive for heroin and a lower proportion of syringes testing positive for amphetamines than the other 
two sites. This can be explained by the fact that, until April 2019 (only 2 months before the collection), clients 
of the drug consumption room were allowed to inject only heroin. One needle tested positive for fentanyl 
mixed with heroin and one needle tested positive for tetrahydrocannabinol (THC), the principal psychoactive 
constituent of cannabis, most likely originating from traces of blood in the needle or from external 
contamination. 
Cologne: heroin and cocaine 
The team from Cologne joined the network in 2018. In the 2018 campaign, 163 out of the 167 syringes 
analysed tested positive for a drug. Cocaine (112 syringes, 69 %) and heroin (112 syringes, 69 %) were 
detected in an equal proportion of syringes, and were found together (‘speedball’) in 60 syringes (37 % of 
syringes containing at least one drug). Fentanyl was detected in one of the syringes containing cocaine and 
heroin. A similar picture emerged in 2019, when cocaine (106 syringes, 73 %) and heroin (118, 81 %) still 
dominated, with 78 syringes containing both drugs. The only syringe containing fentanyl also contained 
heroin, cocaine and doxepin. As in Oslo, one syringe tested positive for THC. 
These results are broadly in line with data from a survey conducted in Cologne in 2013, five years before the 
first ESCAPE campaign, among 322 people who inject drugs recruited through respondent-driven sampling in 
the city (Wenz et al., 2016). At the time of the survey, 85 % of respondents reported using heroin in the last 30 
days, 47 % cocaine, 2 % crack cocaine and 1 % methamphetamine. Cologne was also the city where German 
health authorities detected an increase in HIV infections among people who inject drugs occurring in 2018 
(EMCDDA, 2020a). A total of 12 new HIV diagnoses were reported based on the analysis of laboratory data, 
which constituted an increase from previous years. The injection of stimulants has been associated with 
higher HIV risk as a result of higher levels of unsafe sex and unsafe injecting practices (Cavazos-Rehg et al., 





2009). The documented HIV outbreak among people who inject drugs in Cologne adds to the list of other 
recent HIV outbreaks potentially linked to an increase in stimulant injection: Dublin in 2014-15 (synthetic 
cathinones, alpha-PVP; Giese et al., 2015), Luxembourg in 2014-17 (cocaine; Arendt et al., 2019), Glasgow in 
2015 (cocaine; McAuley et al., 2019) and Munich in 2016 (synthetic cathinones; EMCDDA, 2020a). 
Limitations 
The limitations described in the first ESCAPE report also apply to the 2018 and 2019 campaigns (EMCDDA, 
2019a). The number of syringes collected and tested cannot be translated into a number of individual users. A 
small number of users could have contributed a disproportionately large number of syringes, for example 
users who had returned syringes to collection facilities in bulk. In addition, some syringes may have been 
used by several people. The method therefore does not measure prevalence of injecting nor does it 
necessarily provide the relative prevalence of use for different substances among people who inject drugs. 
For example, the high proportion of syringes containing residues of stimulants could reflect a higher frequency 
of injecting among stimulant users than among non-stimulant users, rather than a higher prevalence of 
stimulant use than other drug use among people who inject drugs. However, information obtained from other 
sources (surveys among people who inject drugs) tends to confirm the relative importance of stimulant 
injecting. 
Drugs in syringes may degrade over time and might become undetectable. The time lag between injection 
and collection was unknown for syringes collected from street bins and low-threshold services. In drug 
consumption rooms, however, syringes were collected immediately after injection. In the case of heroin, 
metabolites and degradation products can indicate the presence of the drug in the syringes even after it has 
degraded, and it was possible to account for that in these studies. This does not apply to other substances, 
however, and therefore the presence of some drugs in syringes may have been underestimated. 
There were several potential selection biases. First, the collection sites within a city were not necessarily 
representative of the city as a whole or of its population of people who inject drugs. Most locations were 
chosen because they hosted harm reduction services or automatic injection-kit dispensers. They were 
therefore representative of only the people who inject drugs using these services or automatic injection-kit 
dispensers. The studies described basic characteristics of the most likely source populations in each city, but 
it could not be ruled out that the syringes collected came from very specific subgroups of people who inject 
drugs, leading to different selection biases across collection sites. Likewise, the ESCAPE network is not 
necessarily representative of all European cities. Second, the exclusion criteria for syringes at collection and 
analysis varied slightly across sites. This might also have introduced a selection bias. Large-volume syringes 
(> 1 ml) were collected in Amsterdam, Helsinki, Oslo and Vilnius, but not in other cities. Some field reports 
suggest that larger syringes (2 ml) are the preferred choice for the injection of diverted opioid substitution 
medications. The study might therefore have underestimated the injection of opioid substitution medications in 
Budapest, Cologne, Lausanne and Paris. 
The detection of a drug in a syringe indicates that the syringe may have been used to inject the drug. An 
alternative explanation is that the drug (or its metabolite) has come from traces of blood drawn into the syringe 
during an injection. In such a case, the user would have consumed the drug prior to the injection, possibly 
through other modes of administration (e.g. smoking, snorting). This study did not test for the presence of 
blood in syringes and it was therefore difficult to identify the exact source of the drug or metabolite. While this 
might have led to an overestimation of the prevalence of injected substances that are commonly smoked by 





people who inject drugs, some elements suggest that this measurement bias is minimal. First, the sensitivity 
of the laboratory methods is expected to be higher for substances directly introduced by the syringe than for 
substances coming from traces of blood (personal communication from laboratory experts). Second, while 
cannabis is the most prevalent smoked drug in Europe (and assuming it is also common among people who 
inject drugs), the ESCAPE study sites that tested for THC found that very few syringes tested positive for it. 
Within the scope of this study, it was not possible to distinguish a syringe containing multiple drugs that had 
been used once (simultaneous or co-use) from a syringe that had been reused by one user (polydrug use) or 
from a syringe that had been used by several users (sharing of syringes). 
In terms of analysis, the main results presented are crude proportions based on relatively small sample sizes. 
No statistical tests for comparisons across cities or over time were applied. However, changes in collection 
sites over time were documented to assess whether changes in patterns over time were more likely to have 
been due to changes in the source population or to changes in the injecting practices of a given population. 
Conclusions 
The 2018 and 2019 campaigns have confirmed some major findings of the 2017 campaign and highlighted 
some new patterns of injecting drug use across a sample of European cities. 
Overall, a wide range of substances are injected by people who inject drugs and strong differences between 
cities reflect the diversity and complexity of the European drug situation. This diversity is both geographical 
and temporal (changes over time). The geographical diversity means that tailored local public health 
responses are required to tackle local issues. The temporal diversity means that it is important to be aware of 
what is happening in other European cities to ensure adequate levels of preparedness (as changes in one city 
might occur in another city in the future). 
While all injecting practices are associated with excess morbidity and mortality, two injecting patterns 
observed in the latest ESCAPE campaigns associated with specific health risks deserve particular attention. 
First, the high prevalence of stimulants (cocaine, synthetic cathinones) in syringes observed in most cities 
across all campaigns should alert public health professionals to the increased risk of acquiring blood-borne 
and sexually transmitted infections among users. This risk has already materialised in Glasgow (a 
participating city in 2017) and Cologne, where recent HIV outbreaks among people who inject drugs have 
been documented. Injecting stimulants typically requires increased provision of harm reduction interventions 
such as NSPs and an adaptation of services to deal with more unstable clients. 
Second, carfentanil, a potent opioid, was detected in a large proportion of syringes from Vilnius, which joined 
the network in 2019. While the detection of fentanyl and its derivatives remains rare in other participating 
cities, the very high overdose risk associated with these substances, the dynamic nature of the European drug 
market and the US opioid crisis driven in part by fentanyl and its derivatives are sufficient reasons to be 
vigilant. Moreover, being a sentinel network with a limited number of collection sites, the ESCAPE network 
might not capture the full extent of the use of fentanyl and its derivatives for injecting. Public health responses 
to limit mortality related to the injection of fentanyl and its derivates include access to take-home naloxone (to 
prevent overdoses) and greater access to substitution treatment (to reduce injecting and harmful use). 





The timely, laboratory-confirmed local data on injected substances and patterns of injection provided by the 
ESCAPE approach can help guide local responses. The results of the campaigns were disseminated locally in 
a number of ways. Summaries of the results were shared with participating low-threshold agencies, providing 
laboratory-confirmed information on substances injected to health and social workers, who can then adapt 
their prevention messages and interventions for drug users accordingly. Local reports were shared with the 
national focal points to triangulate the information obtained with other data sources at the local and national 
levels (treatment data, forensic analysis, wastewater data), providing additional analytical capacity to monitor 
drug use. 
The ESCAPE approach complements existing monitoring tools but does not replace them. Well-designed 
observational studies, collecting behavioural data and qualitative information from interviews with drug users 
in low-threshold services, and using respondent-driven sampling are still the best tools to obtain information 
on many aspects of injecting, including the reuse and sharing of injecting equipment. 
The 2020 ESCAPE campaign will include more sites and reach a total of 10 sentinel cities throughout Europe. 
It will assess the impact, if any, that the COVID-19 pandemic has had on injecting drug use. The network is 
also actively looking to broaden its geographical scope with new collaborations with EU neighbouring 
countries, from the Mediterranean region and eastern Europe, which are also facing evolving public health 
challenges linked to injecting drug use. 
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Amphetamines Amphetamine x x x x x x x x 
Methamphetamine x x x x x x x x 
Cocaine Cocaine x x x x x x x x 
Heroin Heroin x x x x x x x x 
Morphine Morphine x x x x x x x x 
Buprenorphine Buprenorphine x x x x x x x x 
Naloxone Naloxone x x x x x x x x 
Methadone Methadone x x x x x x x x 
Fentanyl and 
derivatives 
3-Methylfentanyl x x x x x  
 
x 
4-Chloro-isobutyrfentanyl x x x x x x 
 
x 
4-Fluoro-isobutyryl fentanyl x x x x x x 
 
x 
4-Methoxy-butyryl fentanyl x x x x x x 
 
x 
Acetylfentanyl x x x x x x x x 
Acrylfentanyl x x x x x x 
 
x 
Alfentanil x x x x x x 
 
x 
Butyrylfentanyl x x x x x x 
 
x 
Carfentanil x x x x x x x x 
Cyclopentylfentanyl x x x x x  
 
x 
Cyclopropylfentanyl x x  x x x 
 
x 
Despropionylfentanyl x x  x x  
 
x 
Fentanyl x x x x x x x x 
Furanyl fentanyl x x x x x x x x 
Ocfentanyl x x x x x x x x 
ortho-Fluorofentanyl x x x x x  
 
x 
Valerylfentanyl x x x x x x 
 
x 
Other opioids AH-7921 x x x x x  
 
x 
Codeine x x x x x x x x 
Dihydrocodeine x x x x x  
 
x 
Hydrocodone x x x x x  
 
x 
Isotonitazene  x  x   x 
Oxycodone x x x x x  
 
x 
Tramadol x x x x x x x x 
U-47700 x x x x x  x x 
Cathinones 3-MMC x x x x x x x x 
3,4-DMMC x x x x x  
 
x 
4-Chloro-alpha-PVP x x x x x  
 
x 
4-Chloroethcathinone x x x x x  
 
x 
4-Chloromethcathinone x x x x x  
 
x 
4-Chloro-alpha-PPP  x x x   x 
4-Chloro-Pentedrone  x  x    x 
4-Fluoro-alpha-PVP x x x x x  
 
x 
4-MEC x x x x x x x x 
Alpha-PBP  x  x    x 
alpha-PEP (PV8) x x x x x   x 
alpha-PHP x x x x x  
 
x 
alpha-PHPp x x x x x  
 
x 
alpha-PVP x x x x x x x x 
Alpha-PVT  x x x    x 
bk-MDDMA x x x x x  
 
x 
Buphedrone (MABP) x x x x x  
 
x 
Butylone (bk-MDMB) x x x x x  
 
x 
Dipentylone  x  x   x 
































































Ephylone (bk-EBDB)  x x x    x 
Ethylone (bk-MDEA) x x x x x  
 
x 
F-alpha-PHP x x  x x  x 
MDPBP x x x x x  
 
x 
MDPPP  x x x   x 
MDPV x x x x x x x x 
Mephedrone (4-MMC) x x x x x x x x 
Methedrone (bk-PMMA) x x x x x  
 
x 
Methylone x x x x x x x x 
Mexedrone x x x x x  
 
x 
N-acetyl mephedrone  x  x   x 
N-ethyl-pentedrone  x  x    x 
Naphyrone x x x x x  
 
x 
N-ethylhexedrone x x x x x  
 
x 
N-ethylnorpentedrone  x  x   x 










5F-APINACA x x  x x x 
 
x 
5F-MDMB-PINACA x x  x x  
 
x 
5F-PB-22 x x  x x x 
 
x 
AB-CHMINACA x x  x x  
 
x 
AB-FUBINACA x x  x x  
 
x 
AMB-FUBINACA x x  x x  
 
x 
MMB-CHMINACA  x  x   x 
Benzodiazepines 3OH-Phenazepam x x x x x  
 
x 
Alprazolam x x x x x x x x 
Bromazepam x x x x x  
 
x 
Chlordiazepoxide x x x x x  
 
x 
Clobazam x x x x x  
 
x 
Clonazepam x x x x x x x x 
Clonazolam x x x x x  
 
x 
Delorazepam x x x x x  
 
x 
Deschloroetizolam x x x x x  
 
x 
Desmethyldiazepam x x x x x x 
 
x 
Diazepam x x x x x x x x 
Diclazepam x x x x x x 
 
x 
Etizolam x x x x x x x x 
Flubromazepam x x x x x x 
 
x 
Flubromazolam x x x x x x 
 
x 
Flunitrazepam x x x x x x x x 
Lorazepam x x x x x  
 
x 
Lormetazepam x x x x x  
 
x 
Meclonazepam x x x x x  
 
x 
Metizolam x x x x x  
 
x 
Midazolam x x x x x x x x 
Nifoxipam x x x x x  
 
x 
Nitrazepam x x x x x x 
 
x 
Oxazepam x x x x x x x x 
Phenazepam x x x x x x 
 
x 
Pyrazolam x x x x x  
 
x 
Temazepam x x x x x  x x 
Piperidines 2-DPMP 
 












4-Fluoro-methylphenidate x x x x x  
 
x 
Ethylphenidate x x x x x x x x 
Methylphenidate x x x x x x x x 
MDMA MDA x x x x x  x x 
MDEA x x x x x  x x 
































































MDMA x x x x x x x x 
Ketamine Ketamine x x x x x x x x 
Other medicines Bupropion x x x x x  
 
x 
Carbamazepine x x x x x  
 
x 
Doxepin  x x x   x 
Etorecoxib  x  x    x 
Gabapentin x x x x x  
 
x 
Methiopropamine x x x x x x x x 
Methotrexate x x x x x  x x 
Piracetam  x x x    x 
Pregabalin x x x x x  
 
x 
Propranolol  x x x   x 
Quetiapine x x x x x  
 
x 
Sertraline  x x x   x 
Tiapride x x x x x  
 
x 
Tizanidine x x x x x  
 
x 
Zolpidem x x x x x x x x 
Zopiclone x x x x x x x x 
Other 
amphetamines 
3-Fluoromethamphetamine x x  x x  
 
x 
4-Fluoro-amphetamine x x x x x  x x 
F-ethamphetamine  x  x    x 
N-acetylamphetamine  x  x    x 
N-propylamphetamine x x  x x  
 
x 
PMA x x x x x  
 
x 
PMMA x x  x x  x 
Other drugs 5-EAPB x x x x x  x x 
Amisulpride  x x x    x 
Mephtetramine x x x x x   x 




6-monoacetylmorphine (heroin) x x x x x x x x 
Meconin (opiate) X x x     x 
7-Aminoclonazepam (clonazepam) x x x x x x 
 
x 

















α-Hydroxy-alprazolam (alprazolam) x x x x x  
 
x 
α-Hydroxy-midazolam (midazolam) x x x x x  
 
x 
Acetylcodeine (heroine)  x x x x x  
 
x 
Amphetamine AC  x     x 
Benzoylecgonine (cocaine) x x x x x x x x 
Ecgonine methyl ester  x x    x x 
EDDP (methadone) x x x x x  
 
x 
HMMA (MDMA) x x  x x  
 
x 
Hydrocotarnine  x     x 
Metamizole breakdown  x x     x 
N-[2-(3,4-methylenedioxyphenyl)-1-





Nicotine  x x     x 
Norbuprenorphine (buprenorphine) x x x x x  
 
x 
Norcocaine  x x    x 
Norcodeine  x x     x 
Normorphine  x x     x 
Noscapine  x x     x 
O-desmethyltramadol (tramadol) x x x x x  
 
x 
Ritalinic acid  x x x   x 
Thebromine  x x     x 
Theophylline  x x     x 





































































Dextromethorphan x x x x x x x x 
Dibutylhydroxytoluene  x      x 
Dimethylsulfone  x      x 
Diphenhydramine  x x x    x 





Hydroxyzine x x x x x  
 
x 
Levamisole x x x x x x x x 





Papaverin  x x   x 










 Procaine  x x   x 
(
1
) Substances in bold are included in the minimum required list of substances to be tested for in laboratory analysis.
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(N = 80) (
2
) 
Count % Count % Count % Count % Count % 
Amphetamines 
Amphetamine 25.0 17.7 0.0 0.0 155.0 40.1 0.0 0.0 4.0 5.0 
Methamphetamine 0.0 0.0 0.0 0.0 96.0 24.8 0.0 0.0 0.0 0.0 
Total 25.0 17.7 0.0 0.0 163.0 42.1 0.0 0.0 4.0 5.0 
Cocaine Cocaine 7.0 5.0 112.0 68.7 13.0 3.4 85.0 66.4 39.0 48.8 
Heroin Heroin (
3
) 47.0 33.3 112.0 68.7 0.0 0.0 47.0 36.7 16.0 20.0 
Morphine Morphine 0.0 0.0 1.0 0.6 0.0 0.0 18.0 14.1 10.0 12.5 
Buprenorphine Buprenorphine 0.0 0.0 0.0 0.0 258.0 66.7 1.0 0.8 2.0 2.5 
Naloxone Naloxone 0.0 0.0 0.0 0.0 32.0 8.3 0.0 0.0 0.0 0.0 
Methadone Methadone 4.0 2.8 0.0 0.0 8.0 2.1 0.0 0.0 0.0 0.0 
Fentanyl and derivatives 
Fentanyl 0.0 0.0 1.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 
Total (
1
) 0.0 0.0 1.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 
Other opioids 
Codeine 1.0 0.7 0.0 0.0 0.0 0.0 5.0 3.9 1.0 1.3 
Oxycodone 0.0 0.0 0.0 0.0 4.0 1.0 0.0 0.0 0.0 0.0 
Total 1.0 0.7 0.0 0.0 4.0 1.0 5.0 3.9 1.0 1.3 
Cathinones 
3-MMC 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 33.0 41.3 
4-Chloro-alpha-PVP 34.0 24.1 0.0 0.0 1.0 0.3 0.0 0.0 0.0 0.0 
4-Chloroethcathinone 9.0 6.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
4-Chloromethcathinone 9.0 6.4 0.0 0.0 1.0 0.3 0.0 0.0 0.0 0.0 
4-Chloro-alpha-PPP 1.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
4-Chloro-Pentedrone 1.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
4-Fluoro-alpha-PVP 0.0 0.0 0.0 0.0 5.0 1.3 0.0 0.0 0.0 0.0 
4-MEC 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 15.0 18.8 



























(N = 80) (
2
) 
alpha-PBP 0.0 0.0 0.0 0.0 1.0 0.3 0.0 0.0 0.0 0.0 
alpha-PEP (PV8) 0.0 0.0 0.0 0.0 2.0 0.5 0.0 0.0 0.0 0.0 
alpha-PHP 0.0 0.0 0.0 0.0 10.0 2.6 0.0 0.0 0.0 0.0 
alpha-PVP 0.0 0.0 0.0 0.0 11.0 2.8 0.0 0.0 0.0 0.0 
alpha-PVT 0.0 0.0 0.0 0.0 1.0 0.3 0.0 0.0 0.0 0.0 
Butylone (bk-MBDB) 0.0 0.0 0.0 0.0 1.0 0.3 0.0 0.0 0.0 0.0 
Dipentylone 13.0 9.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Ephylone (bk-EBDB) 0.0 0.0 0.0 0.0 2.0 0.5 0.0 0.0 0.0 0.0 
F-alpha-PHP 0.0 0.0 0.0 0.0 1.0 0.3 0.0 0.0 0.0 0.0 
MDPBP 0.0 0.0 0.0 0.0 1.0 0.3 0.0 0.0 0.0 0.0 
MDPPP 0.0 0.0 0.0 0.0 1.0 0.3 0.0 0.0 0.0 0.0 
MDPV 0.0 0.0 0.0 0.0 2.0 0.5 0.0 0.0 0.0 0.0 
Mephedrone (4-MMC) 10.0 7.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
N-acetyl mephedrone 1.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
N-ethylhexedrone 44.0 31.2 0.0 0.0 2.0 0.5 0.0 0.0 0.0 0.0 
Total 61.0 43.3 0.0 0.0 21.0 5.4 0.0 0.0 41.0 51.3 
Synthetic cannabinoids 
MMB-CHMINACA 0.0 0.0 0.0 0.0 1.0 0.3 0.0 0.0 0.0 0.0 
Total 0.0 0.0 0.0 0.0 1.0 0.3 0.0 0.0 0.0 0.0 
Benzodiazepines 
Diazepam 0.0 0.0 0.0 0.0 9.0 2.3 0.0 0.0 0.0 0.0 
Midazolam 0.0 0.0 0.0 0.0 4.0 1.0 37.0 28.9 0.0 0.0 
Temazepam 0.0 0.0 0.0 0.0 9.0 2.3 0.0 0.0 0.0 0.0 
Total 0.0 0.0 0.0 0.0 14.0 3.6 37.0 28.9 0.0 0.0 
Piperidines 
Ethylphenidate 0.0 0.0 0.0 0.0 1.0 0.3 0.0 0.0 0.0 0.0 
Methylphenidate 0.0 0.0 0.0 0.0 10.0 2.6 1.0 0.8 2.0 2.5 
Total 0.0 0.0 0.0 0.0 10.0 2.6 1.0 0.8 2.0 2.5 
MDMA MDMA 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Ketamine Ketamine 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 































Bupropion 0.0 0.0 0.0 0.0 8.0 2.1 0.0 0.0 0.0 0.0 
Etorecoxib 0.0 0.0 0.0 0.0 1.0 0.3 0.0 0.0 0.0 0.0 
Gabapentin 0.0 0.0 0.0 0.0 6.0 1.6 0.0 0.0 0.0 0.0 
Pregabalin 0.0 0.0 0.0 0.0 11.0 2.8 0.0 0.0 0.0 0.0 
Propranolol 0.0 0.0 0.0 0.0 2.0 0.5 0.0 0.0 0.0 0.0 
Sertraline 0.0 0.0 0.0 0.0 1.0 0.3 0.0 0.0 0.0 0.0 
Tizanidine 0.0 0.0 0.0 0.0 5.0 1.3 0.0 0.0 0.0 0.0 
Zolpidem 0.0 0.0 0.0 0.0 3.0 0.8 1.0 0.8 0.0 0.0 
Total 0.0 0.0 0.0 0.0 35.0 9.0 1.0 0.8 0.0 0.0 
Other drugs Total 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Other amphetamines 
F-ethamphetamine 0.0 0.0 0.0 0.0 2.0 0.5 0.0 0.0 0.0 0.0 
N-acetylamphetamine 4.0 2.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Total 4.0 2.8 0.0 0.0 2.0 0.5 0.0 0.0 0.0 0.0 
Metabolites and degradation 
products 
Benzoylecgonine 0.0 0.0 102.0 62.6 6.0 1.6 0.0 0.0 0.0 0.0 
Ritalinic acid 0.0 0.0 0.0 0.0 2.0 0.5 0.0 0.0 0.0 0.0 
Total 0.0 0.0 102.0 62.6 8.0 2.1 0.0 0.0 0.0 0.0 
Adulterants 
Caffeine 82.0 58.2 102.0 62.6 0.0 0.0 65.0 50.8 0.0 0.0 
Hydroxyzine 0.0 0.0 0.0 0.0 0.0 0.0 4.0 3.1 0.0 0.0 
Levamisole 1.0 0.7 24.0 14.7 3.0 0.8 70.0 54.7 0.0 0.0 
Lidocaine 0.0 0.0 0.0 0.0 0.0 0.0 3.0 2.3 0.0 0.0 
Paracetamol 48.0 34.0 112.0 68.7 0.0 0.0 32.0 25.0 0.0 0.0 
Phenacetin 0.0 0.0 5.0 3.1 0.0 0.0 61.0 47.7 0.0 0.0 
Total 97.0 68.8 128.0 78.5 3.0 0.8 101.0 78.9 0.0 0.0 
(
1
) Totals can be less than the sum of positive counts within the drug category, since one syringe can contain more than one substance from the same category. 
(
2
) N refers to the number of syringes testing positive for drugs from at least one drug category (excluding syringes testing positive exclusively for metabolites, degradation products and/or adulterants). 
(
3
) Includes reclassification based on combinations of 6-MAM (a metabolite of heroin) with morphine or codeine or meconin (degradation products of heroin). 
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(N = 132) (
2
) 
Count % Count % Count % Count % Count % Count % Count % Count % 
Amphetamines 
Amphetamine 1.0 0.9 2.0 1.9 4.0 2.7 60.0 30.9 0.0 0.0 77.0 49.0 0.0 0.0 2.0 1.5 
Methamphetamine 80.0 68.4 0.0 0.0 0.0 0.0 19.0 9.8 0.0 0.0 7.0 4.5 20.0 12.4 3.0 2.3 
Total 81.0 69.2 2.0 1.9 4.0 2.7 64.0 33.0 0.0 0.0 78.0 49.7 20.0 12.4 4.0 3.0 
Cocaine Cocaine 22.0 18.8 2.0 1.9 106.0 72.6 4.0 2.1 92.0 79.3 5.0 3.2 43.0 26.7 2.0 1.5 
Heroin Heroin (
3
) 29.0 24.8 43.0 39.8 118.0 80.8 2.0 1.0 19.0 16.4 113.0 72.0 10.0 6.2 1.0 0.8 
Morphine Morphine 1.0 0.9 0.0 0.0 1.0 0.7 1.0 0.5 26.0 22.4 0.0 0.0 17.0 10.6 2.0 1.5 
Buprenorphine Buprenorphine 0.0 0.0 0.0 0.0 0.0 0.0 130.0 67.0 0.0 0.0 7.0 4.5 11.0 6.8 0.0 0.0 
Naloxone Naloxone 0.0 0.0 0.0 0.0 0.0 0.0 10.0 5.2 0.0 0.0 1.0 0.6 0.0 0.0 0.0 0.0 
Methadone Methadone 0.0 0.0 4.0 3.7 7.0 4.8 1.0 0.5 0.0 0.0 2.0 1.3 4.0 2.5 121.0 91.7 
Fentanyl and derivatives 
Carfentanil 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 43.0 32.6 
Fentanyl 0.0 0.0 0.0 0.0 1.0 0.7 0.0 0.0 0.0 0.0 1.0 0.6 2.0 1.2 0.0 0.0 
Total 0.0 0.0 0.0 0.0 1.0 0.7 0.0 0.0 0.0 0.0 1.0 0.6 2.0 1.2 43.0 32.6 
Other opioids 
Tramadol 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.0 1.2 0.0 0.0 
U-47700 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.6 0.0 0.0 
Total 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.0 1.9 0.0 0.0 
Cathinones 
3-MMC 0.0 0.0 2.0 1.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
4-Chloromethcathinone 0.0 0.0 20.0 18.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
4-MEC 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 7.0 4.4 0.0 0.0 
alpha-PHP 0.0 0.0 0.0 0.0 0.0 0.0 2.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
alpha-PVP 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Mephedrone (4-MMC) 0.0 0.0 19.0 17.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 104.0 64.6 0.0 0.0 
Methylone 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.6 0.0 0.0 
N-ethyl-pentedrone 0.0 0.0 4.0 3.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
N-ethylhexedrone 0.0 0.0 6.0 5.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
N-ethylnorpentedrone 0.0 0.0 8.0 7.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 







































(N = 132) (
2
) 
Total 0.0 0.0 59.0 54.6 0.0 0.0 2.0 1.0 0.0 0.0 0.0 0.0 108.0 67.1 0.0 0.0 
Synthetic cannabinoids Total 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Benzodiazepines 
Alprazolam 0.0 0.0 0.0 0.0 0.0 0.0 2.0 1.0 0.0 0.0 3.0 1.9 0.0 0.0 0.0 0.0 
Clonazepam 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 7.0 4.5 0.0 0.0 0.0 0.0 
Diazepam 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Midazolam 0.0 0.0 0.0 0.0 0.0 0.0 6.0 3.1 38.0 32.8 0.0 0.0 0.0 0.0 0.0 0.0 
Temazepam 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Total 0.0 0.0 4.0 3.7 0.0 0.0 9.0 4.6 38.0 32.8 10.0 6.4 0.0 0.0 0.0 0.0 
Piperidines Total 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
MDMA MDMA 31.0 26.5 0.0 0.0 0.0 0.0 3.0 1.6 0.0 0.0 3.0 1.9 6.0 3.7 3.0 2.3 
Ketamine Ketamine 9.0 7.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.6 0.0 0.0 
Other medicines 
Doxepin 0.0 0.0 0.0 0.0 3.0 2.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Gabapentin 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Piracetam 0.0 0.0 4.0 3.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Quetiapine 0.0 0.0 0.0 0.0 1.0 0.7 1.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Tizanidine 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Zolpidem 0.0 0.0 0.0 0.0 0.0 0.0 2.0 1.0 0.0 0.0 0.0 0.0 3.0 1.9 0.0 0.0 
Total 0.0 0.0 4.0 3.7 4.0 2.7 5.0 2.6 0.0 0.0 0.0 0.0 3.0 1.9 0.0 0.0 
Other drugs 
Amisulpride 0.0 0.0 0.0 0.0 2.0 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
THC 0.0 0.0 0.0 0.0 1.0 0.7 0.0 0.0 0.0 0.0 1.0 0.6 0.0 0.0 0.0 0.0 
Total 0.0 0.0 0.0 0.0 3.0 2.1 0.0 0.0 0.0 0.0 1.0 0.6 0.0 0.0 0.0 0.0 
Other amphetamines Total 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Metabolites and 
degradation products 
6-monoacetylmorphine 0.0 0.0 0.0 0.0 7.0 4.8 0.0 0.0 0.0 0.0 4.0 2.6 0.0 0.0 0.0 0.0 
Acetylcodeine 0.0 0.0 0.0 0.0 112.0 76.7 2.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Amphetamine AC 1.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Benzoylecgonine 6.0 5.1 0.0 0.0 93.0 63.7 2.0 1.0 0.0 0.0 0.0 0.0 21.0 13.0 0.0 0.0 
Ecgonine methyl ester 0.0 0.0 0.0 0.0 77.0 52.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 







































(N = 132) (
2
) 
EDDP 0.0 0.0 3.0 2.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Hydrocotarnine 2.0 1.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
N-[2-(3,4-methylenedioxyphenyl)-1-
methylvinyl]-N,N-dimethylamine 
28.0 23.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Nicotine 0.0 0.0 0.0 0.0 30.0 20.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Norcocaine 0.0 0.0 0.0 0.0 77.0 52.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Norcodeine 0.0 0.0 0.0 0.0 3.0 2.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Normorphine 0.0 0.0 0.0 0.0 6.0 4.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Noscapine 0.0 0.0 0.0 0.0 124.0 84.9 1.0 0.5 0.0 0.0 0.0 0.0 19.0 11.8 1.0 0.8 
O-desmethyltramadol 0.0 0.0 3.0 2.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Thebromine 0.0 0.0 0.0 0.0 7.0 4.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Theophylline 0.0 0.0 0.0 0.0 2.0 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Total 31.0 26.5 6.0 5.6 146.0 100.0 4.0 2.1 0.0 0.0 4.0 2.6 21.0 13.0 1.0 0.8 
Adulterants 
Caffeine 21.0 18.0 0.0 0.0 113.0 77.4 8.0 4.1 49.0 42.2 0.0 0.0 0.0 0.0 0.0 0.0 
Dextromethorphan 0.0 0.0 0.0 0.0 0.0 0.0 2.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 2.0 1.5 
Dibutylhydroxytoluene 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 7.0 5.3 
Dimethylsulfone 70.0 59.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Diphenhydramine 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 127.0 96.2 
Griseofulvin 0.0 0.0 0.0 0.0 2.0 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Levamisole 0.0 0.0 0.0 0.0 22.0 15.1 0.0 0.0 68.0 58.6 0.0 0.0 18.0 11.2 0.0 0.0 
Lidocaine 0.0 0.0 0.0 0.0 15.0 10.3 0.0 0.0 13.0 11.2 0.0 0.0 0.0 0.0 0.0 0.0 
Papaverin 0.0 0.0 0.0 0.0 115.0 78.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Paracetamol 10.0 8.6 43.0 39.8 116.0 79.5 0.0 0.0 19.0 16.4 0.0 0.0 0.0 0.0 0.0 0.0 
Phenacetin 2.0 1.7 0.0 0.0 5.0 3.4 0.0 0.0 73.0 62.9 0.0 0.0 0.0 0.0 0.0 0.0 
Procaine 0.0 0.0 0.0 0.0 17.0 11.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Total 93.0 79.5 43.0 39.8 137.0 93.8 8.0 4.1 92.0 79.3 0.0 0.0 18.0 11.2 128.0 97.0 
 







) Totals can be less than the sum of positive counts within the drug group, since one syringe can contain more than one substance from the same group. 
(
2
) N refers to the number of syringes testing positive for drugs from at least one drug group (excluding syringes testing positive exclusively for metabolites, degradation products and/or adulterants). 
(
3
) Includes reclassification based on combinations of 6-MAM (metabolite of heroin) with morphine or codeine or meconin (degradation products of heroin). 
 






Most frequent combinations of drug categories found in syringes (data cover syringes containing drugs 
from only two or more drug categories), by city, ESCAPE network 2019 (drug combinations are indicated by 
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